2024

June Maxvax's RSV vaccine was accepted for IND by China's CDE

June Maxvax completed series C+ funding

May Maxvax was consistently listed as one of China's top innovative biotech companies

February Maxvax finished series C funding

2023

January The recombinant rotas virusvaccine entered phase II clinical trial.

May The recombinant herpes zoster vaccine entered phase II clinical trial.

2022

November Maxvax completed round B+ financing.

July Maxvax completed round B financing.

June Construction of Shanghai production center started.

January Maxvax obtained approval for clinical trial of the recombinant herpes zoster vaccine.

January Maxvax Chengdu R&D center was opened.

2021

December The recombinant trivalent rotavirus subunit vaccine entered phase I clinical trial.

July Maxvax completed round A financing.

May Maxvax obtained approval for clinical trial of the recombinant trivalent rotavirus subunit vaccine.

March Wholly-owned subsidiary Shanghai Anyikang Biotechnology was established.

January Wholly-owned subsidiary Shanghai Maikekang Biotechnology was established.

2020

June Wholly-owned subsidiary Chengdu Huarenkang Biotechnology was established.

March Maxvax completed pre-A+ round financing.

2019

December Maxvax completed Pre-A round financing.

2018

September Maxvax was awarded Top 50 Enterprises with the Most Investment Value in China.

August Contolled subsidiary Chengdu Yisikang Pharmaceutical Technology was established.

2017

December Maxvax completed angel financing.

September Maxvax's first human vaccine project was launched.

2016

April Maxvax was founded by Dr. Dexiang Chen in Chengdu.